COST-EFFECTIVENESS ANALYSIS OF RIVAROXABAN VERSUS DABIGATRAN AND ENOXAPARIN FOR THE PREVENTION OF VENOUS THROMBOEMBOLISM AFTER TOTAL KNEE REPLACEMENT

被引：0
|
作者：
Vorobyev, P. [1 ]
Krasnova, L. [2 ]
Borisenko, O. [1 ]
Lukyantseva, D. [2 ]
Bashlakova, L. [2 ]
机构：
[1] Russian Soc Pharmacoecon & Outcomes Res, Moscow, Russia
[2] Moscow State Med Univ, Moscow, Russia
来源：
VALUE IN HEALTH | 2011年 / 14卷 / 03期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A41 / A41
页数：1
相关论文
共 50 条
  • [21] Economic Evaluation of Rivaroxaban Versus Enoxaparin for Prevention of Venous Thromboembolism After Total Knee Replacement and Total Hip Replacement: A Systematic Review
    Rashki Kemmak, Asma
    Abutorabi, Ali
    Alipour, Vahid
    CLINICAL DRUG INVESTIGATION, 2020, 40 (08) : 715 - 725
  • [22] A systematic review of rivaroxaban versus enoxaparin in the prevention of venous thromboembolism after hip or knee replacement
    Song Turun
    Liao Banghua
    Yin Yuan
    Li Zhenhui
    Nie Ying
    Chen Jin
    THROMBOSIS RESEARCH, 2011, 127 (06) : 525 - 534
  • [23] COST-EFFECTIVENESS OF RIVAROXABAN VERSUS ENOXAPARIN FOR THROMBOPROPHYLAXIS AFTER TOTAL HIP REPLACEMENT IN SPAIN
    Diamantopoulos, A.
    Forster, F.
    Brosa, M.
    Lees, M.
    Pinol, C.
    Febrer, L.
    VALUE IN HEALTH, 2008, 11 (06) : A533 - A533
  • [24] COST-EFFECTIVENESS OF DABIGATRAN ETEXILATE FOR THE PRIMARY PREVENTION OF VENOUS THROMBOEMBOLISM IN PATIENTS UNDERGOING TOTAL HIP OR TOTAL KNEE REPLACEMENT SURGERY
    Wolowacz, S.
    Roskell, N.
    Maciver, F.
    Beard, S.
    Robinson, P.
    Plumb, J.
    VALUE IN HEALTH, 2008, 11 (06) : A404 - A404
  • [25] Dabigatran versus Enoxaparin in the prevention of venous thromboembolism after total knee arthroplasty: A randomized clinical trial
    Mirdamadi, Ahmad
    Dashtkar, Solmaz
    Kaji, Mahboobeh
    Pazhang, Farzad
    Haghpanah, Behnam
    Gharipour, Mojgan
    ARYA ATHEROSCLEROSIS, 2014, 10 (06) : 292 - 297
  • [26] COST-UTILITY ANALYSIS OF RIVAROXABAN COMPARED WITH ENOXAPARIN IN PREVENTION OF VENOUS THROMBOEMBOLISM AFTER TOTAL HIP REPLACEMENT IN SLOVAKIA
    Pereira, R.
    Diamantopoulos, A.
    Bielik, J.
    Lees, M.
    Tomek, D.
    Lukac, M.
    VALUE IN HEALTH, 2010, 13 (03) : A166 - A166
  • [27] Cost-effectiveness impact of rivaroxaban versus new and existing prophylaxis for the prevention of venous thromboembolism after total hip or knee replacement surgery in France, Italy and Spain
    Monreal, Manuel
    Folkerts, Kerstin
    Diamantopoulos, Alex
    Imberti, Davide
    Brosa, Max
    THROMBOSIS AND HAEMOSTASIS, 2013, 110 (05) : 987 - 994
  • [28] A Cost-Effectiveness Model Comparing Rivaroxaban and Dabigatran Etexilate with Enoxaparin Sodium as Thromboprophylaxis after Total Hip and Total Knee Replacement in the Irish Healthcare Setting
    Laura McCullagh
    Lesley Tilson
    Cathal Walsh
    Michael Barry
    PharmacoEconomics, 2009, 27 : 829 - 846
  • [29] A Cost-Effectiveness Model Comparing Rivaroxaban and Dabigatran Etexilate with Enoxaparin Sodium as Thromboprophylaxis after Total Hip and Total Knee Replacement in the Irish Healthcare Setting
    McCullagh, Laura
    Tilson, Lesley
    Walsh, Cathal
    Barry, Michael
    PHARMACOECONOMICS, 2009, 27 (10) : 829 - 846
  • [30] COST-EFFECTIVENESS OF APIXABAN VERSUS ENOXAPARIN FOR THE PREVENTION OF POSTSURGICAL VENOUS THROMBOEMBOLISM IN KOREA
    Oh, J. J.
    Shin, H. H.
    Jung, H.
    Park, J. H.
    Ko, S. K.
    VALUE IN HEALTH, 2012, 15 (07) : A633 - A634
12345